REG - Indivior PLC - Indivior Files Form 20-F for US Listing

IndiviorAnnouncement

23/05/2023 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230523:nRSW4129Aa&default-theme=true

RNS Number : 4129A  Indivior PLC  23 May 2023

Indivior PLC Form 20-F Registration Statement for Additional US Listing Now
Available;

Trading on NASDAQ Expected to Commence on June 12th

 

Richmond, VA, May 23, 2023 - Indivior PLC (LSE: INDV) today announced that
its registration statement on Form 20-F required for the additional U.S.
listing of its ordinary shares is now available at www.sec.gov
(http://www.sec.gov) and under the "Investors" section of the Company's
website (www.indivior.com). Trading in Indivior's ordinary shares on the
NASDAQ Global Select Market is expected to commence at the open on June 12,
2023, subject to approval by the U.S. Securities & Exchange Commission
(SEC) and NASDAQ. Indivior will retain its premium listing on the London Stock
Exchange (LSE) and inclusion in the FTSE 250 index, and its ordinary shares
will trade on both exchanges under the ticker symbol "INDV". The Company also
notes that no shares are being offered as part of the additional U.S. listing.

 

Immediately prior to the additional U.S. listing, Indivior's current American
Depository Receipt (ADR) program managed by J.P. Morgan (OTC US: INVVY) will
be terminated. All Indivior American depository shares representing Indivior
shares will be mandatorily cancelled and exchanged for Indivior ordinary
shares on a 1:1 basis. Further information regarding this exchange process has
been communicated separately to ADR holders by J.P. Morgan.

 

Important Cautionary Note Regarding Forward-Looking Statements

This announcement contains certain statements that are
forward-looking. Forward-looking statements include, among other things,
statements regarding the timing of our planned additional U.S. stock
exchange listing and the timing of the planned commercial launch of
OPVEE, and other statements containing the words "believe", "anticipate",
"plan", "expect", "intend", "estimate", "forecast," "strategy," "target,"
"guidance," "outlook," "potential", "project", "priority," "may", "will",
"should", "would", "could", "can", "outlook," "guidance", the negatives
thereof, and variations thereon and similar expressions. By their nature,
forward-looking statements involve risks and uncertainties as they relate to
events or circumstances that may or may not occur in the future.

 

Actual results may differ materially from those expressed or implied in such
statements because they relate to future events. Various factors may cause
differences between Indivior's expectations and actual results, including,
among others, the material risks described in the most recent Indivior PLC
Annual Report and in subsequent releases; our ability to commercialize and
market acceptance of new products; the substantial litigation and ongoing
investigations to which we are or may become a party; our reliance on third
parties to manufacture commercial supplies of most of our products, conduct
our clinical trials and at times to collaborate on products in our pipeline;
our ability to comply with legal and regulatory settlements, healthcare laws
and regulations, requirements imposed by regulatory agencies and payment and
reporting obligations under government pricing programs; risks related to the
manufacture and distribution of our products, some of which are controlled
substances; market acceptance of our products as well as our ability to
commercialize our products and compete with other market participants; the
uncertainties related to the development of new products, including through
acquisitions, and the related regulatory approval process; our dependence on a
small number of significant customers; our ability to retain key personnel or
attract new personnel; our dependence on third-party payors for the
reimbursement of our products and the increasing focus on pricing and
competition in our industry; unintended side effects caused by the clinical
study or commercial use of our products; our use of hazardous materials in our
manufacturing facilities; our import, manufacturing and distribution of
controlled substances; our ability to successfully execute acquisitions,
partnerships, joint ventures, dispositions or other strategic acquisitions;
our ability to protect our intellectual property rights and the substantial
cost of litigation or other proceedings related to intellectual property
rights; the risks related to product liability claims or product recalls; the
significant amount of laws and regulations that we are subject to, including
due to the international nature of our business; macroeconomic trends and
other global developments such as the COVID-19 pandemic; the terms of our debt
instruments, changes in our credit ratings and our ability to service our
indebtedness and other obligations as they come due; changes in applicable tax
rate or tax rules, regulations or interpretations; and our ability to realize
our deferred tax assets.

 

Forward-looking statements speak only as of the date that they are made and
should be regarded solely as our current plans, estimates and beliefs. Except
as required by law, we do not undertake and specifically decline any
obligation to update, republish or revise forward-looking statements to
reflect future events or circumstances or to reflect the occurrences of
unanticipated events.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat addiction and serious mental illnesses.
Our vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of substance use disorder (SUD). Indivior is dedicated to transforming SUD
from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in 39
countries worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Media Contacts:

 

US Media:

Ben Atkins

Vice President, Communications

Indivior PLC

Tel: 424-844-3244

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts:

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSESFWDEDSESI